[The influence of galenic and biologic factors on the bioavailability of Berlocombin].
The analysis of the influence of galenical and biological factors on the biological availability of Berlocombin (sulfamerazin and trimethoprim combination) has been performed by a single Berlocombin juice administration compared to tablets and by a tablet administration combined with nourishment. In case of the juice administration, the biological availability of trimethoprim and sulfamerazin has been reduced. The tablet administration at an empty stomach and a subsequent 5-h waiting period revealed a more complete trimethoprim resorption, which compared to an administration immediately after the standard breakfast is expressed by a significantly greater area under the concentration-time curve (AUC) in serum. In tablet application subsequent to a fatty breakfast, the trimethoprim and sulfamerazin resorption is compared to the relative group some increased; the differences, however, were insignificant ones. The results of this study failed to be of practical consequences, because the dosage applied and recommended by the producer significantly exceeded the minimum inhibition concentrations in serum and urine 3 h after administration. The required therapeutic level in no case fell short of up to the 12. hour.
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D004041:Dietary Fats / Q000008:administration & dosage; D004338:Drug Combinations / Q000008:administration & dosage / Q000378:metabolism; D004435:Eating; D006801:Humans; D007700:Kinetics; D008297:Male; D013416:Sulfamerazine / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D013607:Tablets; D014295:Trimethoprim / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D000096926:Benzenesulfonamides
D004041:Dietary Fats; D004338:Drug Combinations; D013416:Sulfamerazine; D013607:Tablets; D014295:Trimethoprim; C014230:trimerazine; D000096926:Benzenesulfonamides
Der Einfluss galenischer und biologischer Faktoren auf die Bioverfügbarkeit von Berlocombin.